Open AccessTechnologies for producing platelet masses for regenerative medicine
Author(s) -
S. Shevchenko,
Світлана Шевченко,
M. Rublenko,
Михайло Васильович Рубленко,
Alexander Bonkovskyi,
Олександр Антонович Боньковський
Publication year - 2019
Publication title -
naukovij vìsnik veterinarnoï medicini
Language(s) - English
Resource type - Journals
eISSN - 2415-7589
pISSN - 2310-4902
DOI - 10.33245/2310-4902-2019-152-2-105-117
Subject(s) - platelet , centrifugation , regenerative medicine , platelet rich plasma , biomedical engineering , hemostasis , chemistry , thrombopoiesis , medicine , microbiology and biotechnology , stem cell , surgery , chromatography , biology , progenitor cell , megakaryocyte
The development of regenerative medicine is to improve existing and to search for new tools for morphological and functional tissue repair, among which plasma or brin enriched with platelets (PRP and PRF) can be signi cant. Autogenic platelet masses stimulate collagen synthesis, induce vascular growth, reduce pain, provide hemostasis, accelerate regeneration, reduce the risk of postoperative infectious and in ammatory complications, and also have powerful osteoinductive properties. Due to the ability to produce the majority of growth factors, platelets can a ect all stages of the in ammatory-regenerative process, and therefore their biological products are of great importance in solving the problems of regenerative medicine. The technologies for obtaining PRP and PRF are based on centrifugation of blood, as a result of which its active components are concentrated in certain areas of the centrifuge. Blood sampling with or without an anticoagulant, as well as modi cation of centrifugation protocols, allows to obtain various forms of platelet masses, such as a liquid, gel or clots. They are classi ed, depending on the cellular content and architecture of brin, into several categories, namely: pure plasma enriched in platelets (P-PRP), plasma enriched in leukocytes and platelets (L-PRP); injectable brin enriched with platelets (i-PRF) and pure brin enriched with platelets (P-PRF), as well as brin enriched with white blood cells and platelets (L-PRF). The main di erence in the manufacture of PRP compared to PRF is the use of anticoagulants and activators, as well as the possibility of using two-stage centrifugation. Platelet mass is used as an independent component mainly to stimulate the restoration of muscle tissue, to heal chronic wounds, to treat articular pathologies, and in combination with other materials, in particular to replace bone defects. The mechanisms of in uence of each of the categories of platelet mass on tissue regeneration remains poorly understood. It is necessary to standardize the protocols for their preparation, taking into account the in uence of additional substances, such as platelet activators or blood clotting and anticoagulants, as well as optimization of the methods for using each of the platelet mass forms.Key words: platelets, PRP, PRF, centrifuges, centrifugal force.